Giuseppe Di Lorenzo

Summary

Publications

  1. doi request reprint Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients
    Giuseppe Di Lorenzo
    University Federico II, Naples, Italy
    Anticancer Drugs 20:277-80. 2009
  2. ncbi request reprint How to carry out retrospective studies in metastatic renal cell cancer: two caveats that should be avoided
    Giuseppe Di Lorenzo
    Dipartimento di Endocrinologia e Oncologia Clinica e Molecolare, Universita Federico II, Napoli, Italy
    Expert Rev Anticancer Ther 12:331-3. 2012
  3. doi request reprint EGFR mutational status in penile cancer
    Giuseppe Di Lorenzo
    University Federico II, Genitourinary Cancer Section and Rare Cancer Center, Medical Oncology Division, Napoli, Italy
    Expert Opin Ther Targets 17:501-5. 2013
  4. doi request reprint Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis
    Giuseppe Di Lorenzo
    Genitourinary Cancer Section and Rare Cancer Center, University Federico II, Naples, Italy
    BJU Int 110:E661-6. 2012
  5. doi request reprint Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study
    Giuseppe Di Lorenzo
    Genitourinary Oncology and Rare Cancer Center, Federico II University, Naples, Italy
    Eur Urol 60:1280-4. 2011
  6. ncbi request reprint New perspectives in the therapy of castration resistant prostate cancer
    Pasquale Rescigno
    Genitourinary Cancer Section, Medical Oncology Division, Department of Endocrinology and Oncology, University Federico II, Napoli, Italy
    Curr Drug Targets 13:1676-86. 2012
  7. doi request reprint Sipuleucel-T (Provenge®) for castration-resistant prostate cancer
    Giuseppe Di Lorenzo
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi Federico II, Napoli, Italy
    BJU Int 110:E99-104. 2012
  8. doi request reprint Update on classic Kaposi sarcoma therapy: new look at an old disease
    Giuseppe Di Lorenzo
    Department of Clinical and Molecular Oncology, Federico II University, Naples, Italy
    Crit Rev Oncol Hematol 68:242-9. 2008
  9. ncbi request reprint Hormone refractory prostate cancer (HRPC): present and future approaches of therapy
    G Di Lorenzo
    Dipartimento di Endocrinologia Molecolare e Clinica, Cattedra di Oncologia, Universita degli Studi di Napoli Federico II, Via Pansini 5, 80131 Naples, Italy
    Int J Immunopathol Pharmacol 19:11-34. 2006
  10. ncbi request reprint Phase II trial of gemcitabine, prednisone, and zoledronic acid in pretreated patients with hormone refractory prostate cancer
    Giuseppe Di Lorenzo
    Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi di Napoli Federico II, Napoli, Italy
    Urology 69:347-51. 2007

Detail Information

Publications92

  1. doi request reprint Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients
    Giuseppe Di Lorenzo
    University Federico II, Naples, Italy
    Anticancer Drugs 20:277-80. 2009
    ..Paclitaxel is well tolerated and associated with promising efficacy. Further trials, also in a neoadjuvant setting, are needed to corroborate our preliminary findings...
  2. ncbi request reprint How to carry out retrospective studies in metastatic renal cell cancer: two caveats that should be avoided
    Giuseppe Di Lorenzo
    Dipartimento di Endocrinologia e Oncologia Clinica e Molecolare, Universita Federico II, Napoli, Italy
    Expert Rev Anticancer Ther 12:331-3. 2012
    ..Although the evidence provided by retrospective studies is weak, their role in highlighting matters of clinical relevance deserving investigation is undoubtful, as demonstrated by the retrospective study discussed in this paper...
  3. doi request reprint EGFR mutational status in penile cancer
    Giuseppe Di Lorenzo
    University Federico II, Genitourinary Cancer Section and Rare Cancer Center, Medical Oncology Division, Napoli, Italy
    Expert Opin Ther Targets 17:501-5. 2013
    ..Clinical data are available on the role of epidermal growth factor receptors (EGFR) inhibitors in PC but no EGFR mutational analysis has been conducted...
  4. doi request reprint Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis
    Giuseppe Di Lorenzo
    Genitourinary Cancer Section and Rare Cancer Center, University Federico II, Naples, Italy
    BJU Int 110:E661-6. 2012
    ..Neutropenia was the most important grade 3-4 side effect observed, occurring in 20% of patients. These data provide confirmation that such a combination regimen is moderately effective and well tolerated in patients with SCCP...
  5. doi request reprint Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study
    Giuseppe Di Lorenzo
    Genitourinary Oncology and Rare Cancer Center, Federico II University, Naples, Italy
    Eur Urol 60:1280-4. 2011
    ..Previously published preliminary findings showed promising activity of paclitaxel in chemotherapy-pretreated metastatic penile cancer...
  6. ncbi request reprint New perspectives in the therapy of castration resistant prostate cancer
    Pasquale Rescigno
    Genitourinary Cancer Section, Medical Oncology Division, Department of Endocrinology and Oncology, University Federico II, Napoli, Italy
    Curr Drug Targets 13:1676-86. 2012
    ..This review describes in detail the latest results obtained with a the most promising agents in prostate cancer, with a focus on CRPC biology and mechanism of resistance to anti-neoplastic treatment...
  7. doi request reprint Sipuleucel-T (Provenge®) for castration-resistant prostate cancer
    Giuseppe Di Lorenzo
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi Federico II, Napoli, Italy
    BJU Int 110:E99-104. 2012
    ..Although the article does not present new data, a new way of assessing immunotherapy efficacy is proposed. This involves measuring 'consecutive' times to progression, in an attempt to capture the delayed effects of immunotherapy...
  8. doi request reprint Update on classic Kaposi sarcoma therapy: new look at an old disease
    Giuseppe Di Lorenzo
    Department of Clinical and Molecular Oncology, Federico II University, Naples, Italy
    Crit Rev Oncol Hematol 68:242-9. 2008
    ..Among chemotherapeutic agents, recent data are offered from current trials that have focused on the role of pegylated liposomal doxorubicin as first- and second-line therapy...
  9. ncbi request reprint Hormone refractory prostate cancer (HRPC): present and future approaches of therapy
    G Di Lorenzo
    Dipartimento di Endocrinologia Molecolare e Clinica, Cattedra di Oncologia, Universita degli Studi di Napoli Federico II, Via Pansini 5, 80131 Naples, Italy
    Int J Immunopathol Pharmacol 19:11-34. 2006
    ..This article focuses on combinations recently evaluated or under clinical development for the treatment of HRPC...
  10. ncbi request reprint Phase II trial of gemcitabine, prednisone, and zoledronic acid in pretreated patients with hormone refractory prostate cancer
    Giuseppe Di Lorenzo
    Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi di Napoli Federico II, Napoli, Italy
    Urology 69:347-51. 2007
    ....
  11. ncbi request reprint Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: a phase II study
    Giuseppe Di Lorenzo
    Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi Federico II, Naples, Italy
    World J Gastroenterol 13:6553-7. 2007
    ..To improve the results of New therapeutic strategies in hepatocellular carcinoma (HCC). We have conducted a phase II study with pegylated liposomal doxorubicin (PLD), 5-fluorouracil (5FU) and folinic acid (FA)...
  12. ncbi request reprint Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer: a phase I clinical trial
    Giuseppe Di Lorenzo
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi di Napoli Federico II, Napoli, Italy
    Cancer Biol Ther 6:313-7. 2007
    ..This is a phase I study investigating the toxicity and the potential efficacy of thalidomide and oral cyclophosphamide in patients with hormone refractory prostate cancer (HRPC), previously treated with docetaxel-based regimens...
  13. ncbi request reprint Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study
    Giuseppe Di Lorenzo
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi Federico II, Napoli, Italy
    Eur Urol 52:1020-7. 2007
    ..The current study investigated the combination of docetaxel, vinorelbine, and zoledronic acid as a first-line treatment for HRPC...
  14. doi request reprint Phase 1/2 study of intravenous paclitaxel and oral cyclophosphamide in pretreated metastatic urothelial bladder cancer patients
    Giuseppe Di Lorenzo
    Department of Clinical and Molecular Oncology, Federico II University, Naples, Italy
    Cancer 115:517-23. 2009
    ....
  15. ncbi request reprint Pegylated liposomal doxorubicin as second-line therapy in the treatment of patients with advanced classic Kaposi sarcoma: a retrospective study
    Giuseppe Di Lorenzo
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Naples, Italy
    Cancer 112:1147-52. 2008
    ..The current retrospective study investigated the activity and toxicity of PLD in pretreated patients with aggressive, nonvisceral CKS...
  16. ncbi request reprint Hormone-refractory prostate cancer: where are we going?
    Giuseppe Di Lorenzo
    Department of Clinical and Molecular Oncology, Federico II University, Naples, Italy
    Drugs 67:1109-24. 2007
    ..Vaccine therapy offers an active immunological approach for combating malignancy in a targeted manner...
  17. doi request reprint Irinotecan in the treatment of elderly patients with advanced colorectal cancer
    Javier Sastre
    Medical Oncology Department, San Carlos Hospital, c Martin Lagos s n, 28040 Madrid, Spain
    Crit Rev Oncol Hematol 68:250-5. 2008
    ..This revision has been focused in the role of irinotecan in elderly patients...
  18. ncbi request reprint Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis
    G Di Lorenzo
    Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita Federico II, Napoli
    Ann Oncol 20:1535-42. 2009
    ..We reviewed cardiac adverse events in patients with metastatic renal cell carcinoma (RCC) who underwent treatment with this agent...
  19. doi request reprint Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer
    Giuseppe Di Lorenzo
    Dipartimento di Endocrinologia ed Oncologia Clinica e Molecolare, Universita Federico II, Napoli, Italy
    J Clin Oncol 27:4469-74. 2009
    ..We conducted a multicenter study to determine the activity and tolerability of sorafenib as second-line therapy after sunitinib progression in MRCC...
  20. doi request reprint Toxicities of targeted therapy and their management in kidney cancer
    Giuseppe Di Lorenzo
    Department of Endocrinology and Medical Oncology, Genitourinary Cancer Section, University Federico II, Napoli, Italy
    Eur Urol 59:526-40. 2011
    ..Oncologists must be familiar with the management of toxicity that these biologic agents cause, as such toxicity is different from that of conventional chemotherapeutic agents...
  21. doi request reprint Immunotherapy for the treatment of prostate cancer
    Giuseppe Di Lorenzo
    Department of Endocrinology and Medical Oncology, Genitourinary Cancer Section, University Federico II, Via Pansini 5, Naples, Italy
    Nat Rev Clin Oncol 8:551-61. 2011
    ..We present the clinical developments in the field of immunotherapy and critically analyze methodological issues related to the evaluation of tumor responses to immunotherapy, trial design, and surrogate end points...
  22. ncbi request reprint Pegylated liposomal doxorubicin in stage IVB mycosis fungoides
    G Di Lorenzo
    Dipartimento di Patologia Sistematica, Clinica Dermatologica, Universita di Napoli Federico II, Naples, Italy
    Br J Dermatol 153:183-5. 2005
    ..Previous studies have shown that pegylated liposomal doxorubicin (LD) is effective in the treatment of relapsing or recalcitrant cutaneous T-cell lymphoma...
  23. ncbi request reprint Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer
    Giuseppe Di Lorenzo
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Universita degli Studi Federico II, Naples, Italy
    Eur Urol 46:712-6. 2004
    ..The current study investigated the clinical benefit, the impact on biochemical and objective response and tolerability of weekly docetaxel with vinorelbine (VIN-DOX) in symptomatic patients with hormone refractory prostate cancer (HRPC)...
  24. ncbi request reprint FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder
    Giuseppe Di Lorenzo
    Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Seconda Universita degli Studi, Naples, Italy
    Jpn J Clin Oncol 34:747-50. 2004
    ..We conducted a study using FOLFOX-4 (oxaliplatin, fluorouracil, folinic acid) in pre-treated advanced bladder cancer patients...
  25. ncbi request reprint Expression of biomarkers modulating prostate cancer progression: implications in the treatment of the disease
    G Di Lorenzo
    Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi di Napoli Federico II, Naples, Italy
    Prostate Cancer Prostatic Dis 8:54-9. 2005
    ....
  26. doi request reprint Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma
    Giuseppe Di Lorenzo
    Dipartimento di Endocrinologia ed Oncologia Clinica e Molecolare, Universita Federico II, Napoli, Italy
    Eur Urol 58:906-11. 2010
    ..The role of sorafenib, which is approved for second-line treatment after cytokines failure, is presently to be defined...
  27. ncbi request reprint Castration-resistant prostate cancer: current and emerging treatment strategies
    Giuseppe Di Lorenzo
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi Federico II, Naples, Italy
    Drugs 70:983-1000. 2010
    ....
  28. doi request reprint Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer
    Giuseppe Di Lorenzo
    Dipartimento di Endocrinologia ed Oncologia Clinica e Molecolare, Universita Federico II, Napoli, Italy
    BJU Int 107:234-9. 2011
    ..To determine the activity and tolerability of docetaxel re-treatment after first-line therapy with docetaxel in castration-resistant prostate cancer (CRPC)...
  29. ncbi request reprint Management of gynaecomastia in patients with prostate cancer: a systematic review
    Giuseppe Di Lorenzo
    Department of Endocrinology and Molecular and Clinical Oncology, Second University Naples, Naples, Italy
    Lancet Oncol 6:972-9. 2005
    ..In this review, management options for gynaecomastia caused by hormonal manipulation in patients with prostate cancer are discussed...
  30. doi request reprint Metastatic renal cell carcinoma: recent advances in the targeted therapy era
    Giuseppe Di Lorenzo
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi Federico II, Napoli, Italy
    Eur Urol 56:959-71. 2009
    ..The treatment of metastatic renal cell carcinoma (mRCC) has recently evolved from being predominantly cytokine based to being grounded in the use of targeted agents...
  31. ncbi request reprint Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy
    Giuseppe Di Lorenzo
    Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi Federico II, Vico Santo Spirito 54, 80132 Naples, Italy
    J Urol 174:2197-203. 2005
    ..Also, we evaluated their effects on patient hormonal status, quality of life (QOL), sexual function and prostate specific antigen relapse-free survival...
  32. doi request reprint Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study
    Giuseppe Di Lorenzo
    Department of Clinical and Molecular Oncology, Federico II University, Naples, Italy
    Eur Urol 54:1089-94. 2008
    ..No agents are approved for second-line therapy in HRPC, but common standard practice for the oncologists is to treat patients also after docetaxel failure...
  33. doi request reprint Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients
    Carlo Buonerba
    Department of Endocrinology and Medical Oncology, Genitourinary Cancer Section, University Federico II, Naples, Italy
    Cancer Chemother Pharmacol 67:1455-61. 2011
    ..Docetaxel represents the first-line treatment for castration-resistant prostate cancer (CRPC). New therapeutic options are needed for subsequent lines of therapy in CRPC patients...
  34. doi request reprint Peg-filgrastim and cabazitaxel in prostate cancer patients
    Giuseppe Di Lorenzo
    Genitourinary Cancer Section and Rare Cancer Center, Medical Oncology Division, Department of Endocrinology and Oncology, University Federico II, Napoli, Italy
    Anticancer Drugs 24:84-9. 2013
    ..Further analyses involving a larger population are warranted to confirm our results...
  35. doi request reprint Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer
    Carlo Buonerba
    Genitourinary Cancer Section, Medical Oncology Division, Department of Endocrinology and Oncology, University Federico II, Napoli, Italy
    Future Oncol 9:889-97. 2013
    ..This study aimed to identify predictive/prognostic factors in castration-resistant prostate cancer patients treated with cabazitaxel...
  36. ncbi request reprint Medical expulsive treatment of distal-ureteral stones using tamsulosin: a single-center experience
    Marco De Sio
    Department of Urology, Second University, Naples, Italy
    J Endourol 20:12-6. 2006
    ..To evaluate the efficacy of the addition of tamsulosin to our standard expulsive pharmacologic therapy for the treatment of distal-ureteral stones...
  37. ncbi request reprint Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease
    Giuseppe Di Lorenzo
    Department of Oncology, Federico II University, Naples, Italy
    Tumori 89:349-60. 2003
    ..In this article, recent advances in the treatment of hormone-refractory prostate cancer using chemotherapeutic regimens are critically reviewed...
  38. ncbi request reprint HER-2/neu receptor in prostate cancer development and progression to androgen independence
    Giuseppe Di Lorenzo
    Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi Federico II, Naples, Italy
    Tumori 90:163-70. 2004
    ..Finally, clinical trials are in progress in prostate cancer patients to test novel agents that selectively interfere with HER-2/neu activity...
  39. pmc Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml
    Matteo Ferro
    Urology Unit, University Federico II, Naples, Italy
    PLoS ONE 8:e67687. 2013
    ..001 and p = 0.01, respectively). In conclusion, both phi and PCA3 comparably increase the accuracy in predicting the presence of PCa in total PSA range 2-10 ng/ml at initial biopsy, outperforming currently used %fPSA. ..
  40. doi request reprint An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples
    Giuseppe Di Lorenzo
    University Federico II of Napoli, Medical Oncology, Endocrinology and Oncology Department, Naples, Italy
    Expert Opin Pharmacother 12:1491-7. 2011
    ..To date, no trial data exist comparing treatment outcomes for everolimus versus sorafenib. The current analysis indirectly compares the overall survival (OS) benefit of everolimus and sorafenib as second-line treatment options...
  41. ncbi request reprint Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial
    Sisto Perdonà
    Department of Urology, National Tumour Institute, G Pascale Foundation IRCSS, Naples, Italy
    Lancet Oncol 6:295-300. 2005
    ..We aimed to compare tamoxifen with radiotherapy for prevention and treatment of gynaecomastia, breast pain, or both during bicalutamide monotherapy for prostate cancer...
  42. doi request reprint Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers
    Matteo Ferro
    Department of Urology, University of Naples Federico II, Naples, Italy
    Clin Chim Acta 413:1274-8. 2012
    ..In conclusion, %p2PSA, phi and PCA3 may predict a diagnosis of PCa in men undergoing their first prostate biopsy. PCA3 score is more useful in discriminating between HGPIN and non-cancer...
  43. doi request reprint Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy
    Sisto Perdonà
    Urology Unit, IRCCS Fondazione G Pascale, Napoli, Italy
    Prostate 73:227-35. 2013
    ..We assessed the diagnostic performance of these biomarkers, alone or in combination, in men undergoing first prostate biopsy for suspicion of PCa...
  44. ncbi request reprint Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience
    Sisto Perdonà
    Comprehensive Urology Unit, National Tumor Institute, G Pascale Foundation, Naples, Italy
    Cancer 112:75-83. 2008
    ..The authors evaluated their long-term experience with combined-modality, conservative treatment in patients with muscle-invasive bladder cancer...
  45. doi request reprint Combination of docetaxel and cetuximab for penile cancer: a case report and literature review
    Pasquale Rescigno
    Genitourinary Oncology and Rare Cancer Center, Federico II University, Naples, Italy
    Anticancer Drugs 23:573-7. 2012
    ..Only mild mucositis and skin toxicity had been detected. Our case report, the first in the literature, shows that this combination is active and well tolerated in penile squamous cell carcinoma...
  46. pmc Pathological complete response induced by first-line chemotherapy with single agent docetaxel in a patient with advanced non small cell lung cancer
    Ferdinando Riccardi
    UOC Oncologia, Ospedale Cardarelli, Napoli, Italy
    World J Surg Oncol 8:8. 2010
    ..Nevertheless, preoperative chemotherapy or radiotherapy might offer a chance for these patients for radical surgical resection and, possibly, complete recovery...
  47. pmc Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer
    Giuseppe Cancello
    Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Universita Federico II, Via Sergio Pansini, 5, 80131 Napoli, Italy
    Breast Cancer Res 10:R60. 2008
    ..We also compared survival of these patients with that of those who halted trastuzumab at first PD...
  48. ncbi request reprint How to decrease pain during transrectal ultrasound guided prostate biopsy: a look at the literature
    Riccardo Autorino
    Urology Clinic, Second University, Department of Oncology, Federico II University, Vico Santo Spirito 54, 80132 Naples, Italy
    J Urol 174:2091-7. 2005
    ..There is growing interest among urologists on the need for decreasing pain during transrectal ultrasound (TRUS) guided prostate biopsy...
  49. doi request reprint Combined magnetic resonance spectroscopy and dynamic contrast-enhanced imaging for prostate cancer detection
    Sisto Perdonà
    Urology Section, Istituto Nazionale Tumori, Fondazione G Pascale, Naples, Italy
    Urol Oncol 31:761-5. 2013
    ..The use of magnetic resonance spectroscopy imaging (MRSI) and dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) have emerged as a valid diagnostic tools for prostate cancer (CaP)...
  50. ncbi request reprint Dynamic sentinel node biopsy in clinically node-negative penile cancer versus radical inguinal lymphadenectomy: a comparative study
    Sisto Perdonà
    Department of Urology, National Cancer Institute, Naples, Italy
    Urology 66:1282-6. 2005
    ..To evaluate the reliability and morbidity of dynamic sentinel node biopsy compared with radical inguinal lymphadenectomy (RIL) in the treatment of selected patients with squamous cell penile carcinoma...
  51. ncbi request reprint External beam radiotherapy in bone metastatic prostate cancer: impact on patients' pain relief and quality of life
    Giuseppe Di Lorenzo
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi di Napoli Federico II, Napoli, Italy
    Oncol Rep 10:399-404. 2003
    ..Minimal side effects were experienced and QoL improved as shown by the results of the specific questionnaire...
  52. ncbi request reprint Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer
    Giuseppe Di Lorenzo
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi di Napoli Federico II, 80131 Naples, Italy
    Clin Cancer Res 8:3438-44. 2002
    ..We investigated EGFR and c-erbB-2 expression in primary androgen-dependent and in advanced androgen-independent prostate cancer and their potential role as markers of disease progression...
  53. doi request reprint What happens to the abstracts presented at the Societè Internationale d'Urologie meeting?
    Riccardo Autorino
    Clinica Urologica, Seconda Universita degli Studi, Napoli, Italy
    Urology 71:367-71. 2008
    ....
  54. ncbi request reprint The use of tamsulosin in the medical treatment of ureteral calculi: where do we stand?
    Riccardo Autorino
    Department of Urology, Second University, Naples, Italy
    Urol Res 33:460-4. 2005
    ..This selective alpha-blocker should therefore be included in the pharmacological regimen of patients when a conservative approach is considered in the treatment of ureteral lithiasis...
  55. doi request reprint A comprehensive outlook on intracerebral therapy of malignant gliomas
    Carlo Buonerba
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi Federico II, Naples, Italy
    Crit Rev Oncol Hematol 80:54-68. 2011
    ....
  56. doi request reprint Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial
    Giuseppe Di Lorenzo
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Naples, Italy
    Cancer 116:1893-900. 2010
    ..The efficacy of intravesical gemcitabine was evaluated compared with repeated administration of bacille Calmette-Guérin (BCG) after BCG failure in high-risk, non-muscle-invasive bladder cancer (BC)...
  57. ncbi request reprint Four-year outcome of a prospective randomised trial comparing bipolar plasmakinetic and monopolar transurethral resection of the prostate
    Riccardo Autorino
    Clinica Urologica, Seconda Universita degli Studi, Napoli, Italy
    Eur Urol 55:922-9. 2009
    ..No data have been published on the midterm efficacy of bipolar transurethral resection of the prostate (TURP)...
  58. ncbi request reprint Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patients
    Carlo Buonerba
    Genitourinary Cancer Section, Medical Oncology Division, Department of Clinical Medicine, University Federico II, Napoli, Italy
    Future Oncol 10:1353-60. 2014
    ..Conclusion: Our preliminary findings support the hypothesis that carboplatin plus etoposide may yield some clinical benefit in a population of patients who failed all currently approved therapeutic options for prostate cancer. ..
  59. ncbi request reprint Adrenalectomy: defining its role in the surgical treatment of renal cell carcinoma
    Marco De Sio
    Clinica Urologica, Seconda Universita degli Studi, Naples, Italy
    Urol Int 71:361-7. 2003
    ..We evaluated the characteristics of adrenal involvement and the accuracy of computerized tomography (CT) in the diagnosis of RCC, defining the real need for adrenalectomy during surgical treatment...
  60. doi request reprint Calcitriol: a better option than vitamin D in denosumab-treated patients with kidney failure?
    Carlo Buonerba
    University Federico II, Genitourinary Cancer Section, Medical Oncology Division, Department of Endocrinology and Oncology, Via Pansini, 5 80131 Naples, Italy 39 0817463661 39 0817463661
    Expert Opin Biol Ther 13:149-51. 2013
    ....
  61. doi request reprint Preoperative insulin-like growth factor-binding protein-3 (IGFBP-3) blood level predicts gleason sum upgrading
    Daniela Terracciano
    Department of Cellular and Molecular Biology and Pathology L Califano, University of Naples Federico II, Naples, Italy
    Prostate 72:100-7. 2012
    ..To this aim an easy-available tool is represented by circulating biomarkers. Among these, the best candidates are some molecules involved in PCa pathogenesis such as IGFBP-2 and IGFBP-3, IL-6, and its soluble receptor (SIL-6R)...
  62. ncbi request reprint Can high-dose fotemustine reverse MGMT resistance in glioblastoma multiforme?
    Chiara Gallo
    Department of Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples, 80100 Via Sergio Pansini 5, Naples, Italy
    J Neurooncol 100:311-9. 2010
    ..Although treatment caused two episodes of grade 3-4 thrombocytopenia, a complete response and survival of more than three years were achieved, with a 30% increase in dose intensity compared with the standard fotemustine schedule...
  63. doi request reprint BAG3 protein delocalisation in prostate carcinoma
    Stefania Staibano
    Department of Biomorphological and Functional Sciences, Pathology Section, University Federico II of Naples, School of Medicine, Via S Pansini, 5, 80131, Naples, Italy
    Tumour Biol 31:461-9. 2010
    ..These results indicate that BAG3 intra-cytoplasmic delocalisation is a specific feature of cancer versus non-neoplastic prostate and a candidate new marker for prediction of prostate cancer invasiveness and behaviour...
  64. ncbi request reprint Update on PEG-interferon α-2b as adjuvant therapy in melanoma
    Rossella Di Trolio
    Unit of Medical Oncology and Innovative Therapy, G Pascale Institute of National Tumor Foundation, Naples, Italy
    Anticancer Res 32:3901-9. 2012
    ..This review, after a short summary of interferon α-2b trials, critically analyzes the EORTC18991 trial, as well as the subgroup results and future perspectives for this stage of disease...
  65. ncbi request reprint Vesicourethral anastomosis during radical retropubic prostatectomy: does the number of sutures matter?
    Luigi Gallo
    Department of Urology, National Cancer Institute Pascale Foundation, Naples, Italy
    Urology 69:547-51. 2007
    ..To prospectively evaluate the outcome of radical retropubic prostatectomy using three different techniques of vesicourethral anastomosis (VUA), with a different number of sutures used during this surgical step...
  66. doi request reprint Targeted therapy in the treatment of metastatic renal cell cancer
    Giuseppe Di Lorenzo
    Medical Oncology, University Federico II, Naples, Italy
    Oncology 77:122-31. 2009
    ..Immunotherapy confers a small but significant OS advantage but only for the minority of patients with good prognostic features. The results of these trials and ongoing efforts to improve treatment of MRCC are the focus of this review...
  67. ncbi request reprint Gyrus bipolar versus standard monopolar transurethral resection of the prostate: a randomized prospective trial
    Marco De Sio
    Department of Urology, Seconda Universita di Napoli, Naples, Italy
    Urology 67:69-72. 2006
    ..To compare bipolar plasmakinetic (PK) with standard monopolar transurethral resection of the prostate (TURP)...
  68. doi request reprint Sipuleucel-T for prostate cancer: the immunotherapy era has commenced
    Carlo Buonerba
    Dipartimento di Endocrinologia ed Oncologia Clinica e Molecolare, Universita Federico II, Napoli, Italy
    Expert Rev Anticancer Ther 11:25-8. 2011
    ..Sipuleucel-T opens exciting new paradigms for prostate cancer and increases the possibility of survival prolongation for men with this deadly disease...
  69. doi request reprint Chondroitin sulphate enhances the antitumor activity of gemcitabine and mitomycin-C in bladder cancer cells with different mechanisms
    Matteo Ferro
    Department of Urology, University Federico II, Naples, Italy
    Oncol Rep 27:409-15. 2012
    ..In conclusion, in the human bladder cancer cell line HT-1376 pharmacological combination of CS with GEM or MMC resulted in a strong synergism on cell growth inhibition...
  70. doi request reprint Prostate cancer detection in the "grey area" of prostate-specific antigen below 10 ng/ml: head-to-head comparison of the updated PCPT calculator and Chun's nomogram, two risk estimators incorporating prostate cancer antigen 3
    Sisto Perdonà
    Istituto Nazionale Tumori, Fondazione G Pascale, Napoli, Italy
    Eur Urol 59:81-7. 2011
    ..Prostate cancer antigen 3 (PCA3) holds promise in diagnosing prostate cancer (PCa), but no consensus has been reached on its clinical use. Multivariable predictive models have shown increased accuracy over individual risk factors...
  71. ncbi request reprint Management of AIDS-related Kaposi's sarcoma
    Giuseppe Di Lorenzo
    Department of Molecular and Clinical Endocrinology and Oncology, University of Federico II, Naples, Italy
    Lancet Oncol 8:167-76. 2007
    ....
  72. ncbi request reprint A case of renal melanoma metastasis: description of clinico-pathological features
    Sisto Perdonà
    UOC Urologia, Istituto Nazionale Tumori, Fondazione G Pascale, Napoli, Italy
    Arch Ital Urol Androl 79:161-3. 2007
    ..Patient refused standard systemic chemotherapy/immunotherapy and was treated with sunitinib. At 6 months disease progression was observed...
  73. ncbi request reprint Pathology of the prostate in radical cystectomy specimens: a critical review
    Riccardo Autorino
    Clinica Urologica, Seconda Universita degli Studi, Napoli, Italy
    Surg Oncol 18:73-84. 2009
    ..Poorly differentiated prostate adenocarcinoma and urothelial carcinoma often share overlapping morphologic features and it can be sometimes difficult to differentiate between these two entities...
  74. ncbi request reprint Expression of HECA-452 antigen correlates with disease relapse in mycosis fungoides
    Rossella Di Trolio
    Dermatology Section, Department of Systematic Pathology, University of Naples, Federico II, Naples, Italy
    Anal Quant Cytol Histol 30:203-8. 2008
    ..To determine the expression of HECA-452 epitope in mycosis fungoides (MF), assess whether its expression increases in relapsed MF compared with nonrelapsed MF and determine the potential prognostic relevance of HECA-452 expression...
  75. doi request reprint Ten-year adjuvant treatment with somatostatin analogs in a patient with atypical carcinoid of the lung
    Carlo Buonerba
    Department of Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples, Via Sergio Pansini 5, Naples, Italy
    Anticancer Drugs 21:465-8. 2010
    ..Clinical investigations, conducted in large samples of patients, are necessary to evaluate the effectiveness of such an approach...
  76. pmc Efficacy of rituximab in gastric diffuse large B cell lymphoma patients
    Davide Leopardo
    Department of Endocrinology and Clinical Oncology, University Federico II, 80131, Naples, Italy
    World J Gastroenterol 16:2526-30. 2010
    ..To evaluate retrospectively the efficacy of rituximab plus chemotherapy in gastric diffuse large B cell lymphoma (DLBCL)...
  77. ncbi request reprint Are abstracts presented at the EAU meeting followed by publication in peer-reviewed journals? A critical analysis
    Riccardo Autorino
    Clinica Urologica, Seconda Universita degli Studi, Napoli, Italy
    Eur Urol 51:833-40; discussion 840. 2007
    ..Our goal was to assess the rate and time-course of peer-reviewed publication of abstracts presented at the European Association of Urology (EAU) Annual Meeting and to identify factors predictive of publication...
  78. ncbi request reprint Imatinib mesylate in thymic epithelial malignancies
    Giovannella Palmieri
    Molecular and Clinical Endocrinology and Oncology Department, University Federico II, Via Pansini 5, 80128 Naples, Italy
    Cancer Chemother Pharmacol 69:309-15. 2012
    ....
  79. ncbi request reprint Orbital metastasis as a first indication of prostate cancer: a case report
    Riccardo Autorino
    Clinica Urologica, Seconda Universita degli Studi di Napoli, Italy
    Arch Ital Urol Androl 77:109-10. 2005
    ..A follow-up MRI scan at 6 months showed almost complete involution of the orbital metastatic process. However the disease subsequently progressed and the patient died 22 months after diagnosis...
  80. ncbi request reprint Bicalutamide-induced gynaecomastia: do we have the answer?
    Giuseppe Di Lorenzo
    Eur Urol 52:5-8. 2007
  81. ncbi request reprint Re: Fabio Calabrò and Cora N. Sternberg. Current indications for chemotherapy in prostate cancer patients. Eur urol 2007;51:17-26
    Giuseppe Di Lorenzo
    Eur Urol 52:613-4. 2007
  82. ncbi request reprint Editorial comment on: prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experience
    Giuseppe Di Lorenzo
    Eur Urol 53:332. 2008
  83. ncbi request reprint Re: Börje Ljungberg, Damian C. Hanbury, Marcus A. Kuczyk, Axel S. Merseburger, Peter F.A. Mulders, Jean-Jaques Patard and Ioanel C. Sinescu. Renal cell cacinoma guideline. Eur Urol 2007;51:1502-10
    Giuseppe Di Lorenzo
    Eur Urol 52:926-8; author reply 928. 2007
  84. ncbi request reprint Clinicopathologic features of prostate adenocarcinoma incidentally discovered at the time of radical cystectomy: an evidence-based analysis
    Rocco Damiano
    Clinica Urologica, Università Magna Graecia, Catanzaro, Italy
    Eur Urol 52:648-57. 2007
    ....
  85. doi request reprint Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi's sarcoma: a multicenter study
    Giuseppe Di Lorenzo
    J Invest Dermatol 128:1578-80. 2008
  86. ncbi request reprint Estramustine in prostate cancer: new look at an old drug
    Giuseppe Di Lorenzo
    Lancet Oncol 8:959-61. 2007
  87. ncbi request reprint Prospective clinical trials of biotherapies in solid tumors: a 5-year survey
    Alessandro Ottaiano
    Department of Medical Oncology, ULSS2, Santa Maria del Prato Hospital, via Bagnols Ceze, Feltre BL, Italy
    Cancer Immunol Immunother 54:44-50. 2005
    ..To review the content and quality of prospective clinical trials of biotherapies in solid tumors...
  88. ncbi request reprint An increase in basal cell carcinoma among the young: an epidemiological study in a middle-south Italian population
    Sergio Delfino
    Department of Plastic and Reconstructive Surgery, Section of Dermohystopathology, University La Sapienza, Rome, Italy
    Anticancer Res 26:4979-83. 2006
    ..In conclusion, an increasing incidence of basal cell carcinoma among young people over the past 20 years was reported. No significant difference in tumour aggressiveness between the young and the elderly patients was observed...
  89. ncbi request reprint Survey of modalities of toxicity assessment and reporting in noncomparative prospective studies of chemotherapy in breast cancer
    Francesco Perrone
    Clinical Trials Office, National Cancer Institute, I 80131 Naples, Italy
    J Clin Oncol 20:52-7. 2002
    ..To review how toxicity, a main end point of phase II studies, is assessed and reported in published phase II chemotherapy trials in breast cancer...
  90. ncbi request reprint The need to reduce patient discomfort during transrectal ultrasonography-guided prostate biopsy: what do we know?
    Marco De Sio
    Chair of Urology, Second University, 80132 Naples, Italy
    BJU Int 96:977-83. 2005